Business Context and Reporting Period
This Form 8-K Current Report was filed by Kiora Pharmaceuticals, Inc. on April 1, 2026, covering events occurring on April 1 and April 2, 2026. The company is incorporated in Delaware and trades on the NASDAQ under the symbol KPRX.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are reported in this document.
Material Changes
- Executive Departure: Eric J. Daniels, M.D., MBA, resigned as Chief Development Officer effective April 17, 2026.
- Reason for Departure: The resignation is to pursue another opportunity and did not result from any disagreement regarding the Company's operations, policies, or practices.
- Disclosure: A press release announcing the resignation was issued on April 2, 2026, and is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of material risks and contingencies beyond the standard disclosure regarding the executive departure. The document explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the appointment of a successor to the Chief Development Officer role.
- Review the press release (Exhibit 99.1) for additional context on the transition plan.
- Check subsequent filings for any impact on the company's drug development pipeline or strategic direction.